Skip to main content

Advertisement

Table 2 Post-dosimetric parameters

From: Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil -

  Naftopidil (n=70) Silodosin (n=71) p-value
Median (range) Median (range) (Mann–Whitney U test)
PV (mL) at postdosimetry 26.8 (13.8-47.0) 29.1 (12.4-54.5) 0.031
%D90 (%) 114.1 (91.8-144.5) 115.5 (90.1-138.8) 0.410
D90 (Gy) 169.0 (110.6-213.5) 169.8 (115.9-218.5) 0.638
V100 (%) 95.8 (80.2-99.5) 96.0 (83.1-99.6) 0.378
V150 (%) 60.9 (33.6-87.9) 60.6 (32.5-84.4) 0.800
UD30 (Gy) 204.0 (123.7-267.4) 198.6 (133.0-276.6) 0.939
%UD30 (%) 134.8 (96.1-172.9) 137.9 (106.0-172.9) 0.833
UD90 (Gy) 141.2 (92.7-176.8) 139.1 (86.6-193.7) 0.673
%UD90 (%) 95.8 (63.4-149.2) 94.2 (67.2-121.0) 0.803
R100 (mL) 0.01 (0.00-1.00) 0.03 (0.00-1.00) 0.135
BED (Gy2) 197.7 (154.3-253.2) 202.5 (151.4-246.2) 0.635
  1. PV: prostate volume at post-dosimetry, %D90: minimal percentage of the dose received by 90% of the prostate gland, D90: minimal does (Gy) received by 90% of the prostate gland, V100/V150: percentage of the prostate volume receiving 100% and 150% of the prescribed minimal peripheral dose, %UD30/UD30: minimal percentage of the dose and minimal dose (Gy) received by 30% of the urethra), %UD90/UD90: minimal percentage of the dose and minimal dose (Gy) received by 90% of the urethra, R100: rectal volume (mL) receiving 100% of the prescribed dose, and BED: biologically effective dose.